Resolving Histologic Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programs.
Fernando MagroRish K PaiTaku KobayashiVipul JairathFlorian RiederIsabel RedondoTrevor LissoosNathan MorrisMingyang ShanMeekyong ParkLaurent Peyrin-BirouletPublished in: Journal of Crohn's & colitis (2023)
Early resolution of endoscopic and histologic inflammation with mirikizumab is associated with better UC outcomes.